NLS Novo Nordisk

Novo Nordisk is increasing its drug development capacity by investing 550 million Danish kroner (100 million US dollars) in a new research and development facility in Bagsværd, Denmark. The purification plant will expand the company’s capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs under development. The pilot plant will be fully […]

The Danish insulin maker plans to file for regulatory approval for the company’s new anti-obesity drug in Mexico, reports the Wall Street Journal. Novo Nordisk has reportedly targeted Mexico for an early launch of the treatment due to Mexico’s high percentage of overweight people, according to a statement from Mike Doustdar, senior vice president for international operations […]

Trialbee has developed a web based platform and methodology which enable the Novo Nordisk to perform fast and effective patient recruitment to specific clinical trials. Trialbee helps reduce the time required for recruitment resulting in important efficiency gains for the pharmaceutical company. Novo Nordisk will use Trialbee’s services for e-recruitment of patients to planned studies […]

Novo Nordisk and Oxford University team up to further enhance diabetes research and help the new generation of research leaders. The two have established an international fellowship program with the aim to support the development and career of young, exceptional research talent within diabetes. The new partnership will establish postdoctoral fellowship opportunities that will be […]

Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) have approved its Biologics License Application (BLA) for recombinant coagulation factor VIII, Novoeight. The FDA approved Novoeight for use in adults and children with haemophilia A for control and prevention of bleeding, perioperative management and routine prophylaxis to prevent or reduce the frequency […]

Novo Nordisk teams up with Kymab in an antibody discovery agreement.